- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03885310
INGEST I Pilot Study (INGEST)
Gastrointestinal Drug-Coated Balloon for the Treatment of Symptomatic Recurrent Benign Esophageal Stricture
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is designed to determine the safety and effectiveness of drug coated balloon (DCB) treatments on esophageal stricture.
Up to 30 subjects are planned to be enrolled and treated with the study device at up to 5 clinical sites outside of US. Subjects will be followed up post-treatment to one year and then annually for up to 5 years. The annual follow up after the first year is optional.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Asunción, Paraguay
- Adventista Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 and ≤ 80 years.
- Benign esophageal stricture with diameter less than 10 mm (barium esophagram).
- Dysphagia score of 2 to 4 (Ogilvie Dysphagia Score).
- Recurrent stricture after at least 2 previous balloon/bougie dilation or stricturotomy sessions.
- Stricture total length ≤ 7 cm. Tandem or adjacent strictures are allowed if the strictures are caused by the same underlining disease.
- Ability to undergo periodic endoscopic follow-up.
- Voluntary participation and provided written informed consent.
Exclusion Criteria:
- Pregnancy or breastfeeding or plan to get pregnant in next 12 months.
- Contraindication to endoscopy, anesthesia or deep sedation.
- Benign esophageal stricture due to extrinsic esophageal compression.
- Currently required chest radiation therapy.
- Malignant esophageal stricture.
- Stricture total length > 7 cm or esophageal strictures at multiple locations where the total stricture length exceeds 7 cm
- Dysphagia related to primary motility disorders, such as achalasia, diffused esophageal spasm, ineffective esophageal motility (IEM), hypertensive lower esophageal sphincter, etc.
- Active erosive esophagitis.
- Present esophageal ulceration, perforation, leak, fistula, or varices.
- Concurrent gastric and/or duodenal obstruction.
- Active systemic infection.
- Allergy to paclitaxel or any components of the delivery system.
- Severe coagulation disorders or current use of anticoagulant for comorbidities.
- Chronic steroid use for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use.
- Received steroid injections into target stricture in the last 4 weeks
- Intolerant to proton pump inhibitors.
- Life expectancy of less than 12 months.
- Unwilling or unable to comply with the follow-up study requirements.
- Lacking capacity to provide informed consent.
- Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, recent laparotomy, pharyngeal or cervical deformity, etc.
- Currently participation in another pre-market drug or medical device clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DCB Treatment
Stricture patients treated by DCB
|
The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incident of serious balloon dilation-related complications
Time Frame: 30 days
|
Adverse events such as perforation, bleeding requiring intervention, severe pain during swallowing, infection requiring hospitalization or IV antibiotics, dysphagia requiring re-intervention at determined by the attending physician
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numbers of additional esophageal dilation procedures
Time Frame: 30 days, 3 months, 6 months, and 12 months
|
Repeat stricture treatments
|
30 days, 3 months, 6 months, and 12 months
|
Time to first dysphagia symptom recurrence
Time Frame: 30 days, 3 months, 6 months, and 12 months
|
Ogilvie Dysphagia Score will be used to assess subject's dysphagia symptom changes at follow-ups.
The date of the first reported occurrence of dysphagia symptom will be used to derive the time to first dysphagia symptom recurrence.
|
30 days, 3 months, 6 months, and 12 months
|
Improvement in dysphagia score
Time Frame: 30 days, 3 months, 6 months, and 12 months
|
Ogilvie Dysphagia Score will be used to assess subject's dysphagia symptom changes at follow-ups.
The scores at each follow-up will be compared to the score at baseline.
|
30 days, 3 months, 6 months, and 12 months
|
Esophageal stricture diameter
Time Frame: 30 days, 3 months, 6 months, and 12 months
|
Endoscopy and esophagography will be conducted to measure the internal caliber of the esophagus.
Results will be reported in millimeters.
|
30 days, 3 months, 6 months, and 12 months
|
Technical success
Time Frame: Time of procedure
|
Successful delivery of the drug coated balloon to the target stricture, balloon inflation to the desired pressure, balloon deflation and withdraw without device malfunction.
|
Time of procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kenneth Wang, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR2001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Stricture
-
Federal University of São PauloUnknownEsophageal Stricture | Caustic Esophageal Stricture | Peptic Esophageal Stricture | Post-Surgical Esophageal StrictureBrazil
-
University of Southern CaliforniaUnknownEsophageal Stricture | Duodenal Stricture | Jejunal Stricture | Anastomotic Stricture of Small IntestineUnited States
-
Radboud University Medical CenterELLA-CS , sroUnknownBenign Esophageal Stricture
-
Radboud University Medical CenterUnknownBenign Esophageal StrictureNetherlands
-
Nagasaki UniversityUnknownEsophageal Anastomotic StrictureJapan
-
Mayo ClinicCompletedEsophageal Dilation | Refractory Benign Esophageal StrictureUnited States
-
Mayo ClinicCompletedEsophageal StrictureUnited States
-
Boston Scientific CorporationCompletedRefractory Anastomotic Esophageal StricturesNetherlands, Sweden, Brazil
-
AdventHealthRecruitingEsophageal Stricture | StrictureUnited States
-
Ajou University School of MedicineCompletedEsophageal StrictureKorea, Republic of
Clinical Trials on GIE Drug Coated Balloon
-
GIE MedicalActive, not recruitingBiliary Disease | Biliary Stricture | Biliary Obstruction | Biliary Anastomotic StenosisParaguay
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Cantonal Hospital of St. GallenUnknownRenal InsufficiencySwitzerland
-
Xuanwu Hospital, BeijingUnknownAtherosclerosis of Artery | In-stent Arterial RestenosisChina
-
Ettore Sansavini Health Science FoundationUnknown
-
Xuanwu Hospital, BeijingChanghai Hospital; Fudan University; RenJi Hospital; Huashan Hospital; Chengdu University... and other collaboratorsRecruitingPeripheral Arterial DiseaseChina
-
Assiut UniversityNot yet recruitingDrug Coated Balloon
-
Ulsan Medical CenterRecruitingDrug-coated BalloonKorea, Republic of
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruiting